{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:19:12Z","timestamp":1794572352656,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41591-020-0755-1","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T12:16:27Z","timestamp":1583151387000},"page":"379-386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1179,"title":["Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-8378","authenticated-orcid":false,"given":"Shorena","family":"Janelidze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geidy E.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyun","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas K.","family":"Proctor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Eichenlaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0705-3696","authenticated-orcid":false,"given":"Eric M.","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Dage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"755_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"755_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131\u2013144 (2010).","journal-title":"Nat. Rev. Neurol."},{"key":"755_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14, 989\u2013997 (2018).","journal-title":"Alzheimers Dement."},{"key":"755_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","volume":"12","author":"H Tatebe","year":"2017","unstructured":"Tatebe, H. et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer\u2019s disease and Down Syndrome. Mol. Neurodegener. 12, 63 (2017).","journal-title":"Mol. Neurodegener."},{"key":"755_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3233\/JAD-170810","volume":"61","author":"CC Yang","year":"2018","unstructured":"Yang, C. C. et al. Assay of plasma phosphorylated tau protein (Threonine 181) and total tau protein in early-stage Alzheimer\u2019s disease. J. Alzheimers Dis. 61, 1323\u20131332 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"755_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jalz.2014.07.001","volume":"11","author":"V Chouraki","year":"2015","unstructured":"Chouraki, V. et al. Plasma amyloid-beta and risk of Alzheimer\u2019s disease in the Framingham Heart Study. Alzheimers Dement. 11, 249\u2013257 e241 (2015).","journal-title":"Alzheimers Dement."},{"key":"755_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H. & Blennow, K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 76, 791\u2013799 (2019).","journal-title":"JAMA Neurol."},{"key":"755_CR8","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","volume":"87","author":"N Mattsson","year":"2016","unstructured":"Mattsson, N. et al. Plasma tau in Alzheimer disease. Neurology 87, 1827\u20131835 (2016).","journal-title":"Neurology"},{"key":"755_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamaneurol.2018.4666","volume":"76","author":"MP Pase","year":"2019","unstructured":"Pase, M. P. et al. Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol. 76, 598\u2013606 (2019).","journal-title":"JAMA Neurol."},{"key":"755_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 15, 673\u2013684 (2016).","journal-title":"Lancet Neurol."},{"key":"755_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/jamaneurol.2018.3692","volume":"76","author":"R Smith","year":"2018","unstructured":"Smith, R., Wibom, M., Pawlik, D., Englund, E. & Hansson, O. Correlation of in vivo [18F]Flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol. 76, 310\u2013317 (2018).","journal-title":"JAMA Neurol."},{"key":"755_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.mcn.2018.12.001","volume":"97","author":"M Scholl","year":"2018","unstructured":"Scholl, M. et al. Biomarkers for tau pathology. Mol Cell Neurosci. 97, 18\u201333 (2018).","journal-title":"Mol Cell Neurosci"},{"key":"755_CR13","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1212\/WNL.0000000000006875","volume":"92","author":"R Ossenkoppele","year":"2019","unstructured":"Ossenkoppele, R. et al. Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease. Neurology 92, e601\u2013e612 (2019).","journal-title":"Neurology"},{"key":"755_CR14","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1093\/brain\/aww163","volume":"139","author":"R Smith","year":"2016","unstructured":"Smith, R. et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 139, 2372\u20132379 (2016).","journal-title":"Brain"},{"key":"755_CR15","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","volume":"76","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist, S. et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol. 76, 1060\u20131069 (2019).","journal-title":"JAMA Neurol."},{"key":"755_CR16","unstructured":"Mattsson, N. et al. The implications of different approaches to define ATN in Alzheimer\u2019s disease. Neurology (in the press)."},{"key":"755_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 280\u2013292 (2011).","journal-title":"Alzheimers Dement."},{"key":"755_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jalz.2018.08.014","volume":"15","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist, S. et al. Accurate risk estimation of beta-amyloid positivity to identify prodromal Alzheimer\u2019s disease: cross-validation study of practical algorithms. Alzheimers Dement. 15, 194\u2013204 (2019).","journal-title":"Alzheimers Dement."},{"key":"755_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt163","volume":"5","author":"H Zetterberg","year":"2013","unstructured":"Zetterberg, H. et al. Plasma tau levels in Alzheimer\u2019s disease. Alzheimers Res. Ther. 5, 9 (2013).","journal-title":"Alzheimers Res. Ther."},{"key":"755_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.resuscitation.2012.07.027","volume":"84","author":"J Randall","year":"2013","unstructured":"Randall, J. et al. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation 84, 351\u2013356 (2013).","journal-title":"Resuscitation"},{"key":"755_CR21","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1073\/pnas.89.10.4378","volume":"89","author":"D Couchie","year":"1992","unstructured":"Couchie, D. et al. Primary structure of high molecular weight tau present in the peripheral nervous system. Proc. Natl Acad. Sci. USA 89, 4378\u20134381 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"755_CR22","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.15252\/emmm.201707809","volume":"9","author":"N Mattsson","year":"2017","unstructured":"Mattsson, N. et al. (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer\u2019s disease. EMBO Mol. Med. 9, 1212\u20131223 (2017).","journal-title":"EMBO Mol. Med."},{"key":"755_CR23","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1212\/WNL.0000000000004887","volume":"90","author":"N Mattsson","year":"2018","unstructured":"Mattsson, N. et al. Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology 90, e388\u2013e395 (2018).","journal-title":"Neurology"},{"key":"755_CR24","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato, C. et al. Tau kinetics in neurons and the human central nervous system. Neuron 97, 1284\u20131298 e1287 (2018).","journal-title":"Neuron"},{"key":"755_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach, T. G., Monsell, S. E., Phillips, L. E. & Kukull, W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010. J. Neuropathol. Exp. Neurol. 71, 266\u2013273 (2012).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"755_CR26","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151\u20131162 (2018).","journal-title":"JAMA"},{"key":"755_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","volume":"5","author":"O Hansson","year":"2006","unstructured":"Hansson, O. et al. Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228\u2013234 (2006).","journal-title":"Lancet Neurol."},{"key":"755_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura, A. et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature 554, 249\u2013254 (2018).","journal-title":"Nature"},{"key":"755_CR29","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler, S. E. et al. High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93, e1647\u2013e1659 (2019).","journal-title":"Neurology"},{"key":"755_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2016.05.014","volume":"467","author":"J Kuhlmann","year":"2017","unstructured":"Kuhlmann, J. et al. CSF Abeta1-42 \u2013 an excellent but complicated Alzheimer\u2019s biomarker \u2013 a route to standardisation. Clin. Chim. Acta 467, 27\u201333 (2017).","journal-title":"Clin. Chim. Acta"},{"key":"755_CR31","doi-asserted-by":"publisher","unstructured":"Barth\u00e9lemy, N. R. et al. Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-\u03b2 pathology. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/226977 (2017).","DOI":"10.1101\/226977"},{"key":"755_CR32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28, 595\u2013599 (2010).","journal-title":"Nat. Biotechnol."},{"key":"755_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183\u2013194 (2004).","journal-title":"J. Intern. Med."},{"key":"755_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10918","volume":"7","author":"N Mattsson","year":"2016","unstructured":"Mattsson, N. et al. Increased amyloidogenic APP processing in APOE varepsilon4-negative individuals with cerebral beta-amyloidosis. Nat. Commun. 7, 10918 (2016).","journal-title":"Nat. Commun."},{"key":"755_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archneur.56.1.33","volume":"56","author":"DJ Gelb","year":"1999","unstructured":"Gelb, D. J., Oliver, E. & Gilman, S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56, 33\u201339 (1999).","journal-title":"Arch. Neurol."},{"key":"755_CR36","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov. Disord. 32, 853\u2013864 (2017).","journal-title":"Mov. Disord."},{"key":"755_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan, I. et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele\u2013Richardson\u2013Olszewski Syndrome): report of the NINDS-SPSP International Workshop. Neurology 47, 1\u20139 (1996).","journal-title":"Neurology"},{"key":"755_CR38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong, M. J. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496\u2013503 (2013).","journal-title":"Neurology"},{"key":"755_CR39","unstructured":"The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer\u2019s Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer\u2019s disease. Neurobiol. Aging 18, S1\u2013S2 (1997)."},{"key":"755_CR40","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","volume":"71","author":"S Palmqvist","year":"2014","unstructured":"Palmqvist, S. et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 71, 1282\u20131289 (2014).","journal-title":"JAMA Neurol."},{"key":"755_CR41","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson, O. et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88, 930\u2013937 (2017).","journal-title":"Neurology"},{"key":"755_CR42","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.116.174508","volume":"58","author":"A Hahn","year":"2017","unstructured":"Hahn, A. et al. Modeling strategies for quantification of in vivo (18)F-AV-1451 binding in patients with tau pathology. J. Nucl. Med. 58, 623\u2013631 (2017).","journal-title":"J. Nucl. Med."},{"key":"755_CR43","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass, A. et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer\u2019s disease. Neuroimage 157, 448\u2013463 (2017).","journal-title":"Neuroimage"},{"key":"755_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ana.24711","volume":"80","author":"H Cho","year":"2016","unstructured":"Cho, H. et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann. Neurol. 80, 247\u2013258 (2016).","journal-title":"Ann. Neurol."},{"key":"755_CR45","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.neuroimage.2005.06.058","volume":"28","author":"DC Van Essen","year":"2005","unstructured":"Van Essen, D. C. A Population-Average, Landmark- and Surface-based (PALS) atlas of human cerebral cortex. Neuroimage 28, 635\u2013662 (2005).","journal-title":"Neuroimage"},{"key":"755_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01150-x","volume":"8","author":"S Palmqvist","year":"2017","unstructured":"Palmqvist, S. et al. Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat. Commun. 8, 1214 (2017).","journal-title":"Nat. Commun."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0755-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0755-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0755-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:01:49Z","timestamp":1684605709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-0755-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1038\/s41591-020-0755-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"20 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.J., S.P., E.S. and G.E.S. report no conflicts of interest. N.M. has been a consultant for ADNI. R.S. has served as a (nonpaid) consultant for Roche. H.Z. has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Alzecure and Biogen and is a co-founder of Brain Biomarker Solutions, a GU Ventures-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. K.B. has served as a consultant or at advisory boards for Alector, Biogen, CogRx, Lilly, MagQu, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions, all unrelated to the work presented in this paper. E.M.R. is a scientific advisor to Alzheon, Aural Analytics, Denali, Green Valley, MaQ and United Neuroscience, and to Roche and Roche Diagnostics (compensation for travel only). His NIH-supported studies include research contracts with Avid\/Eli Lilly, Genentech\/Roche and Novartis\/Amgen. O.H. has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals and Euroimmun. In the past 2\u2009years he has received consultancy\/speaker fees (paid to the institution) from Biogen and Roche. T.G.B. has served on a scientific advisory board and has been a consultant for Vivid Genomics and Prothena Biosciences. The sponsors mentioned above had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, nor in preparation, review and approval of the manuscript. U.E. is an employee of the Roche Group. X.C., N.K.P. and J.L.D. are employees of Eli Lilly and Company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}